Plasmodium falciparum dihydrofolate reductase and dihyropteroate synthase mutations and the use of trimethoprim-sulfamethoxazole prophylaxis among persons infected with human immunodeficiency virus

American Journal of Tropical Medicine and Hygiene

Volumn 82, Issue 5, 2010, Pages 766-771

  Malamba, Samuel ^a   Sandison, Taylor ^b   Lule, John ^a   Reingold, Arthur ^c   Walker, Jordan ^d   Dorsey, Grant ^d   Mermin, Jonathan ^e  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Centers for Disease Control and Prevention Kenya   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FOLIC ACID ANTAGONIST;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG USE; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALARIA CONTROL; MALARIA FALCIPARUM; MALE; NONHUMAN; PLASMODIUM FALCIPARUM; UGANDA; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANIMALS; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DIHYDROPTEROATE SYNTHASE; DRUG RESISTANCE; FEMALE; FOLIC ACID; FOLIC ACID ANTAGONISTS; HIV INFECTIONS; HUMANS; MALARIA, FALCIPARUM; MALE; MUTATION; PLASMODIUM FALCIPARUM; TETRAHYDROFOLATE DEHYDROGENASE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; UGANDA; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS; PLASMODIUM FALCIPARUM;

EID: 77952702389     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2010.08-0408     Document Type: Article

References (36)

1. World Health Organization, 2004-2005. Uganda HPV/AIDS Sero-Behavioral Survey (UHSBS). Availabe at: www.who.int/3by5/support/june2005-uga.pdf.
2. Talisuna AO, Erhart A, Samarasinghe S, Van Overmeir C, Speybroeck N, D'Alessandro U, 2006. Malaria transmission intensity and the rate of spread of chloroquine resistant Plasmodium falciparum: why have theoretical models generated conflicting results? Infect Genet Evol 6: 241-248.
3. Okello PE, Van Bortel W, Byaruhanga AM, Correwyn A, Roelants P, Talisuna A, D'Alessandro U, Coosemans M, 2006. Variation in malaria transmission intensity in seven sites throughout Uganda. Am J Trop Med Hyg 75: 219-225. (Pubitemid 46941334)
4. French N, Nakiyingi J, Lugada E, Watera C, Whitworth JA, Gilks CF, 2001. Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS 15: 899-906. (Pubitemid 32424393)
5. Grimwade K, French N, Mbatha DD, Zungu DD, Dedicoat M, Gilks CF, 2004. HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. AIDS 18: 547-554. (Pubitemid 38365884)
6. Korenromp EL, 2005. Malaria attributable to the HIV-1 epidemic, sub-Saharan Africa. Emerg Infect Dis 11: 1410-1419. (Pubitemid 41209136)
7. Abu-Raddad LJ, Patnaik P, Kublin JG, 2006. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science 314: 1603-1606. (Pubitemid 44907155)
8. ter Kuile FO, Parise ME, Verhoeff FH, Udhayakumar V, Newman RD, van Eijk AM, Rogerson SJ, Steketee RW, 2004. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg 71: 41-54.
9. Van Geertruyden JP, Mulenga M, Mwananyanda L, Chalwe V, Moerman F, Chilengi R, Kasongo W, Van Overmeir C, Dujardin JC, Colebunders R, Kestens L, D'Alessandro U, 2006. HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria. J Infect Dis 194: 917-925. (Pubitemid 44454077)
10. Kamya MR, Gasasira AF, Yeka A, Bakyaita N, Nsobya SL, Francis D, Rosenthal PJ, Dorsey G, Havlir D, 2006. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis 193: 9-15. (Pubitemid 43032494)
11. Mermin J, Ekwaru JP, Liechty CA, Were W, Downing R, Ransom R, Weidle P, Lule J, Coutinho A, Solberg P, 2006. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 367: 1256-1261.
12. Anglaret X, Chene G, Attia A, Toure S, Lafont S, Combe P, Manlan K, N'Dri-Yoman T, Salamon R, 1999. Early chemoprophylaxis with trimethoprim- sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 353: 1463-1468. (Pubitemid 29204363)
13. Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, Djomand G, Ackah A, Domoua K, Kadio A, Yapi A, Combe P, Tossou O, Roels TH, Lackritz EM, Coulibaly D, De Cock KM, Coulibaly IM, Greenberg AE, 1999. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet 353: 1469-1475. (Pubitemid 29204364)
14. Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, Farrelly L, Kaganson N, Zumla A, Gillespie SH, Nunn AJ, Gibb DM, 2004. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 364: 1865-1871. (Pubitemid 39536090)
15. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, Kaharuza F, Culver D, Kizito F, Bunnell R, Kigozi A, Nakanjako D, Wafula W, Quick R, 2004. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 364: 1428-1434. (Pubitemid 39370718)
16. Eggena MP, Barugahare B, Okello M, Mutyala S, Jones N, Ma Y, Kityo C, Mugyenyi P, Cao H, 2005. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis 191: 694-701.
17. Gill CJ, Sabin LL, Tham J, Hamer DH, 2004. Reconsidering empirical cotrimoxazole prophylaxis for infants exposed to HIV infection. Bull World Health Organ 82: 290-297. (Pubitemid 38568466)
18. Whitty CJ, Jaffar S, 2002. Plasmodium falciparum cross resistance. Lancet 359: 80.
19. Kamya MR, Bakyaita NN, Talisuna AO, Were WM, Staedke SG, 2002. Increasing antimalarial drug resistance in Uganda and revision of the national drug policy. Trop Med Int Health 7: 1031-1041.
20. Greenwood B, 2004. The use of anti-malarial drugs to prevent malaria in the population of malaria-endemic areas. Am J Trop Med Hyg 70: 1-7. (Pubitemid 39220508)
21. Dorsey G, Dokomajilar C, Kiggundu M, Staedke SG, Kamya MR, Rosenthal PJ, 2004. Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda. Am J Trop Med Hyg 71: 758-763. (Pubitemid 40075626)
22. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, Cowman AF, Winstanley PA, Watkins WM, Nzila AM, 2001. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol 17: 582-588.
23. Kyabayinze D, Cattamanchi A, Kamya MR, Rosenthal PJ, Dorsey G, 2003. Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. Am J Trop Med Hyg 69: 247-252.
24. Malamba SS, Mermin J, Reingold A, Lule JR, Downing R, Ransom R, Kigozi A, Hunt BM, Hubbard A, Rosenthal PJ, Dorsey G, 2006. Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HlV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members. Am J Trop Med Hyg 75: 375-380. (Pubitemid 46941293)
25. Laufer MK, van Oosterhout JJ, Thesing PC, Thumba F, Zijlstra EE, Graham SM, Taylor TE, Plowe CV, 2006. Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. J Infect Dis 193: 872-878.
26. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE, 1995. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 52: 565-568.
27. Duraisingh MT, Curtis J, Warhurst DC, 1998. Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp Parasitol 89: 1-8. (Pubitemid 28377366)
28. Cuzick J, 1985. A Wilcoxon-type test for trend. Stat Med 4: 87-90.
29. Bukirwa H, Yeka A, Kamya MR,Talisuna A, Banek K, Bakyaita N, Rwakimari JB, Rosenthal PJ, Wabwire-Mangen F, Dorsey G, Staedke SG, 2006. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Triak 1: e7.
30. Francis D, Nsobya SL,Talisuna A, Yeka A, Kamya MR, Machekano R, Dokomajilar C, Rosenthal PJ, Dorsey G, 2006. Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. J Infect Dis 193: 978-986.
31. Iyer JK, Milhous WK, Cortese JF, Kublin JG, Plowe CV, 2001. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet 358: 1066-1067. (Pubitemid 32925132)
32. Triglia T, Menting JG, Wilson C, Cowman AF, 1997. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci USA 94: 13944-13949. (Pubitemid 28009689)
33. Kamya MR, Gasasira AF, Achan J, Mebrahtu T, Ruel T, Kekitiinwa A, Charlebois ED, Rosenthal PJ, Havlir D, Dorsey G, 2007. Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS 21: 2059-2066. (Pubitemid 47462155)
34. Thera MA, Sehdev PS, Coulibaly D, Traore K, Garba MN, Cissoko Y, Kone A, Guindo A, Dicko A, Beavogui AH, Djimde AA, Lyke KE, Diallo DA, Doumbo OK, Plowe CV, 2005. Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis 192: 1823-1829. (Pubitemid 41587836)
35. Roper C, Pearce R, Bredenkamp B, Gumede J, Drakeley C, Mosha F, Chandramohan D, Sharp B, 2003. Antifolate antimalarial resistance in southeast Africa: a population-based analysis. Lancet 361: 1174-1181. (Pubitemid 36398386)
36. Dunyo S, Milligan P, Edwards T, Sutherland C, Targett G, Pinder M, 2006. Gametocytaemia after drug treatment of asymptomatic Plasmodium falciparum. PLoS Clin Trials 1: e20.